The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. Lyra Therapeutics Inc.’s current trading price is -32.87% away from its 52-week high, while its distance from the 52-week low is 133.87%. The stock’s price range for this period has been between $1.86 and $6.48 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 0.76 million for the day, a number notably higher than the average daily volume of 0.35 million over the last three months.
The stock of Lyra Therapeutics Inc. (LYRA) is currently priced at $4.35. In the last session, the stock climbed significantly, topping out at $4.86 after opening at $4.78. The day’s lowest price was $4.32 before the stock closed at $4.74.
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free
The market performance of Lyra Therapeutics Inc.’s stock has been turbulent in recent times. Over the last year, the company’s stock reached its highest point at $6.48 on 09/16/22, while the lowest value for the same duration was $1.86 on 03/27/23.
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Lyra Therapeutics Inc. (LYRA) has experienced a quarterly rise of 45.48% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 234.81M and boasts a workforce of 73 employees.
Lyra Therapeutics Inc.: What Analysts Are Saying
As of right now, 4 analysts are rating Lyra Therapeutics Inc. as a BUY, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 3.23, with a change in price of +2.37. Similarly, Lyra Therapeutics Inc. recorded 267,946 in trading volume during the last 100 days, posting a change of +119.70%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for LYRA stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
LYRA Stock Stochastic Average
Lyra Therapeutics Inc.’s raw stochastic average for the past 50 days is presently 61.37%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 57.93%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 69.30% and 74.27%, respectively.
LYRA Stock Price Performance Analysis
The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. The metric has seen a significant gain of 38.54% since the start of this calendar year. Looking back over the last six months, we can see a weaker performance of 111.68%. Over the past 30 days, the price of LYRA has fallen by 20.50%. And in the last five days, it has surged by 12.69%.
